Integrating Full Bayesian Inference and Student's t‐Distribution Method for Enhanced Outlier Handling in Caffeine Population Pharmacokinetics: Assessing Drug–Drug Interactions with Enasidenib in Relapsed or Refractory AML and MDS Patients

Documenti analoghi

• Assessment of CYP‐Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients with Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
  di: Yiming Cheng, et al.
  Pubblicazione: (2024)
• Drug–Drug Interactions and Combination Therapy Strategies of Amiodarone With Digoxin, Rivaroxaban, and Phenytoin Assessed by Physiologically Based Pharmacokinetic Modeling
  di: Youjun Chen, et al.
  Pubblicazione: (2025)
• Disease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis
  di: Medhat M. Said, et al.
  Pubblicazione: (2025)
• Population Pharmacokinetics of Valemetostat and Exposure–Response Analyses of Efficacy and Safety in Patients with Relapsed/Refractory Peripheral T–Cell Lymphoma
  di: Hiroyuki Inoue, et al.
  Pubblicazione: (2025)
• Application of Physiologically Based Pharmacokinetic Modeling to Inform Dose Selection of Mezigdomide in a Phase I Drug–Drug Interaction Study
  di: Joseph Burnett, et al.
  Pubblicazione: (2025)